Patient- and clinician-reported outcomes for the additively manufactured sub-periosteal jaw implant (AMSJI) in the maxilla: a prospective multicentre one-year follow-up study. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Van den Borre, C.; Rinaldi, M.; De Neef, B.; Loomans, N.A.J.; Nout, E.; Van Doorne, L.; Naert, I.; Politis, C.; Schouten, H.; Klomp, G.; Beckers, L.; Freilich, M.M.; Mommaerts, M.Y.
• Is Part Of: International journal of oral & maxillofacial surgery. Volume 51:Issue 2(2022)
• Page Start: 243
• Page End: 250
• Publication Date: 2022-02
• Subjects: maxilla -- edentulous jaw -- sub-periosteal implantation -- alveolar bone loss -- patient satisfaction; Mouth -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Dentistry -- Periodicals; Dentistry, Operative; Oral Surgical Procedures; Surgery, Oral; Dentistry; Maxilla -- Surgery; Mouth -- Surgery; Electronic journals; Periodicals; 617.52059
• DOI: 10.1016/j.ijom.2021.05.015
• Languages: English
• ISSNs: 0901-5027

Abstract

Abstract: The clinical outcomes of maxillary rehabilitation with the additively manufactured sub-periosteal jaw implant (AMSJI; CADskills BV) were evaluated in edentulous patients with a Cawood–Howell atrophy classification ≥5 in all regions of the maxilla. Fifteen consecutive patients were included in the study and followed up for 1 year. They were interviewed using a survey protocol and were examined clinically and radiographically preoperatively (T0) and at 1 (T1), 6 (T2), and 12 (T3) months after permanent upper prosthesis placement. The patients reported an increased oral health-related quality of life. The overall mean Oral Health Impact Profile-14 score at T0 was 17.20 (standard deviation (SD) 6.42). When results at T0 were compared to those at T1 (mean 8.93, SD 5.30), a statistically significant difference was seen ( P = 0.001). At T3, the mean value was 5.80 (SD 4.18). Compared to T0, there was also a statistically significant difference at T3 ( P = 0.001). General satisfaction based on the numerical rating scale was a mean 49.93 at T1, which was less than patient expectation prior to treatment at T0 (52.13). A higher overall value was seen at T3 (53.20) when compared to T0. Within the constraints of the short follow-up, the AMSJI appears to be a promising tool for patients with extreme jaw atrophy. The high patient expectations were met without complications.